A physician-supervised peptide program, built for the audience you have already created.
It runs under your brand, in your voice, to your people. We are the back end — the physicians, the compliant procurement, the platform, the compliance review and the capital. You are never asked to become a healthcare company, and we are never the name on the front.
Demand is at a high, and the compliant lane just opened.
Most of the market is still selling gray-market vials with no doctor behind them. That is the gap.
Twelve peptides came off the list
The FDA removed twelve peptides from its “do not compound” list. In July an advisory committee voted to recommend six more for the 503A Bulks List; the final rule is pending.
The audience is already there
Roughly one in eight American adults now takes a GLP-1, and eligibility is far wider than that.
Nobody is selling the supervision
As branded medication gets cheaper and the gray-market copies get shut down, what people pay for is the doctor, the labs and the follow-up. That is what we run.
Physician-designed programs that match goals your audience already has.
The medical director sets what goes in each one. You point people at the right door.
Recover
Injury, joints, tendons. For someone training around something that will not settle. Supervised, 90-day window, check-in at the end.
Rebuild
Body composition and growth-hormone support. The core 90-day program, layered onto the training they already do.
Reset
Weight management. Physician-supervised: evaluation, labs, an FDA-approved medication where it fits, and real follow-up. The biggest door of the four.
Sustain
After the first 90 days. Lower dose, quarterly labs, ongoing provider access — where most of the long-term value sits, for the patient and for you.
- Step 1
Your link
- Step 2
Intake and labs
- Step 3
Doctor evaluation
- Step 4
Pharmacy ships
- Step 5
90-day check-in
Every patient receives an individual evaluation and a patient-specific prescription filled by a state-licensed pharmacy. You never diagnose, prescribe, or handle patient data.
You bring the brand. We bring everything behind it.
We bring
- Physician-supervised care. Protocols authored by the medical director; every patient individually evaluated by a licensed prescriber.
- Compliant procurement. Registered 503A compounding pharmacy, patient-specific fills, batch tested, cold-chain shipped.
- Patient education. Onboarding, consent, lab guidance and follow-up written by clinicians, not by marketing.
- Compliance and claim review. Counsel on the structure, plus a fast content check before you post.
- Platform, support and capital. HIPAA telehealth platform, support team, back-office automation, and the money to run it.
You bring
- Your subscribers and influence. An audience that already trusts you and already buys from you.
- An existing funnel. App, coaching, apparel — this becomes the premium tier.
- Content in your voice. Your own protocol, your results, your honest take.
- A launch moment. An announcement, follow-ups, and a home for the link.
- Category exclusivity. Inside peptides and hormone programs you promote this one. Every other brand deal you have or want is untouched.
Time commitment: a content day at launch, then a few posts a month on a schedule we agree together. Revenue share is competitive and structured per partnership, calculated on gross — what the patient pays — with lifetime attribution to your link or code, accruing monthly, paid quarterly, against a dashboard you can check any time.
Start as a launch partner. Earn your way into the brand.
- Phase 1
Launch partner. Revenue share, category exclusivity, your link and dashboard. Live in about 90 days.
- Phase 2
Face of the brand. Co-branded protocols and content, the share steps up, and an equity option opens at an agreed milestone.
- Phase 3
What we add next. If it makes sense for both of us, your share extends to whatever we add for the same patients.
Milestone, step-up and equity terms are agreed in writing once Phase 1 data is in.
Four steps from yes to live.
- 1Agree and sign. Terms and attribution in writing, plus a short compliance briefing — what you can and cannot say, kept practical.
- 2Onboard. Platform and provider setup, your link and dashboard live, and content production on whatever schedule and format works for you.
- 3Soft launch. A limited cohort first. We tune intake, support and response times before anything goes wide.
- 4Go public. Full announcement. Dashboard live from day one.
Run a program inside your own practice instead.
If you already have the practice, the engagement is narrower: we set up your protocols and procurement options, hand over templated protocols for your review, and provide the compliance oversight. The program stays yours.
How the program stays inside the lines.
- Product reaches a patient only through a state-licensed pharmacy against a patient-specific prescription. “Research use only” product is excluded entirely.
- Every compound in every protocol is confirmed against the current FDA 503A Bulks List and PCAC status with counsel before it is offered, and re-confirmed on each rule change.
- All marketing and partner content passes a claim review before publication.
- Informed consent states plainly that compounded drugs are not FDA-approved.
- HIPAA safeguards, a documented adverse-event workflow, and records retention.
Start the conversation.
Jason LeDay, Managing Partner — jleday@digihealthsolutions.ai · 972-746-8027
This page describes a business partnership program. It is not medical advice, not an offer of employment, and not an offer to sell securities. Compounded drugs are not FDA-approved. Commercial terms described here are indicative and subject to a definitive agreement.